Equities Analysts Offer Predictions for AXSM FY2024 Earnings

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Equities researchers at William Blair increased their FY2024 EPS estimates for shares of Axsome Therapeutics in a research report issued on Monday, January 13th. William Blair analyst M. Minter now expects that the company will post earnings of ($4.04) per share for the year, up from their previous forecast of ($4.13). The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($4.60) per share. William Blair also issued estimates for Axsome Therapeutics’ Q4 2024 earnings at ($0.84) EPS, Q1 2025 earnings at ($0.95) EPS, Q2 2025 earnings at ($0.55) EPS, Q3 2025 earnings at ($0.23) EPS, Q4 2025 earnings at $0.11 EPS, FY2025 earnings at ($1.62) EPS and FY2026 earnings at $4.74 EPS.

Several other research firms have also recently commented on AXSM. StockNews.com raised shares of Axsome Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th. HC Wainwright reaffirmed a “buy” rating on shares of Axsome Therapeutics in a research report on Tuesday, December 31st. Robert W. Baird lifted their target price on Axsome Therapeutics from $112.00 to $116.00 and gave the company an “outperform” rating in a research report on Wednesday, November 13th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $121.00 price target on shares of Axsome Therapeutics in a research report on Thursday, December 12th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $133.00 price objective on shares of Axsome Therapeutics in a research report on Monday. One equities research analyst has rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. According to MarketBeat, Axsome Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $129.43.

Axsome Therapeutics Stock Up 10.8 %

Axsome Therapeutics stock opened at $93.75 on Thursday. The company has a 50 day moving average of $92.18 and a 200-day moving average of $89.28. The company has a quick ratio of 2.37, a current ratio of 2.44 and a debt-to-equity ratio of 1.97. Axsome Therapeutics has a twelve month low of $64.11 and a twelve month high of $105.00. The stock has a market capitalization of $4.54 billion, a PE ratio of -14.36 and a beta of 1.04.

Axsome Therapeutics (NASDAQ:AXSM) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($1.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.38) by $0.04. The business had revenue of $104.76 million during the quarter, compared to analyst estimates of $98.71 million. Axsome Therapeutics had a negative return on equity of 158.36% and a negative net margin of 91.87%. During the same period in the previous year, the firm earned ($1.32) EPS.

Institutional Investors Weigh In On Axsome Therapeutics

Several hedge funds have recently bought and sold shares of the company. FMR LLC increased its position in Axsome Therapeutics by 20.6% during the third quarter. FMR LLC now owns 1,088,087 shares of the company’s stock worth $97,786,000 after buying an additional 185,951 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Axsome Therapeutics by 2.7% during the 3rd quarter. Geode Capital Management LLC now owns 908,459 shares of the company’s stock worth $81,659,000 after acquiring an additional 23,564 shares during the last quarter. Wellington Management Group LLP increased its holdings in shares of Axsome Therapeutics by 1.1% during the 3rd quarter. Wellington Management Group LLP now owns 742,745 shares of the company’s stock worth $66,750,000 after acquiring an additional 8,125 shares during the last quarter. Millennium Management LLC lifted its holdings in Axsome Therapeutics by 1.4% during the 2nd quarter. Millennium Management LLC now owns 739,819 shares of the company’s stock valued at $59,555,000 after purchasing an additional 10,401 shares during the last quarter. Finally, Hood River Capital Management LLC boosted its position in Axsome Therapeutics by 5.4% during the second quarter. Hood River Capital Management LLC now owns 549,066 shares of the company’s stock worth $44,200,000 after purchasing an additional 28,316 shares during the period. 81.49% of the stock is currently owned by institutional investors and hedge funds.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.